Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China
HONG KONG – 25th July 2025 – Essex Bio-Technology Limited ("Essex" or the "Group," Stock Code: 1061.HK) is delighted to announce that its indirect wholly-owned subsidiary, Zhuhai Essex Bio-Pharmaceutical Company Limited, has received approval from the National Medical Products Administration (NMPA) for the registration and commercialisation of its multi-dose Diquafosol Sodium Eye Drops in the People's Republic of China.
The newly approved product is a multi-dose eye drop formulation containing 3% diquafosol sodium (5 ml:150 mg). It is indicated for the treatment of dry eye syndromes, specifically targeting conditions such as conjunctival epithelium injury and tear abnormalities. Diquafosol sodium, its active pharmaceutical ingredient, functions as a P2Y2 receptor agonist. It works by acting on conjunctival tissues to promote the secretion of tears, including both water and secretory mucins. Furthermore, it may also encourage the expression of...
